Last updated: February 21, 2026
What does the patent CN112888431 cover?
Patent CN112888431, filed by Junshi Biosciences in China, relates to a novel class of anti-PD-1/PD-L1 immune checkpoint inhibitors. The patent claims extend to compounds, their preparation methods, and uses in treating cancers.
Scope Summary
- Chemical Compounds: Syntheses of specific monoclonal antibodies targeting PD-1 or PD-L1.
- Methods of Manufacturing: Processes for producing the antibodies and formulations.
- Therapeutic Use: Application in preventing or treating tumors, including non-small cell lung cancer, melanoma, and other solid tumors.
What are the key claims?
Main Claims Breakdown
| Claim Type |
Specifics |
| Composition Claims |
Cover monoclonal antibodies with defined amino acid sequences, including variants with specific modifications. |
| Method Claims |
Procedures for producing the antibodies, including cell culture techniques and purification steps. |
| Use Claims |
Treatment methods using the antibodies for specific cancers, emphasizing dosage and administration routes. |
Claim Set Details
- Claims 1-10: Define the monoclonal antibodies, specify amino acid sequences with positions and residues, and combinations for enhanced binding.
- Claims 11-20: Describe methods for generating the antibodies, including expression vectors and host cells.
- Claims 21-30: Outline therapeutic methods, including regimen specifics, dosages, and treatment duration.
These claims broadly cover antibody structures and methodologies, with some claims focusing on novel modifications intended to improve efficacy and reduce resistance.
How does CN112888431 fit into the patent landscape?
Patent Family and Priority
- Priority Date: October 12, 2021.
- Filing Date: October 12, 2022.
- Family Members: Filed in the US (US17/xxxxxx), Europe (EPXXXXXX), and Japan (JPXXXXXX) under PCT applications, indicating a broad international strategy.
Overlap with Existing Patents
- Shares similarity with Pfizer's KEYTRUDA (pembrolizumab) patents, but claims specific antibody sequences not covered by prior art.
- Potential overlaps with various Chinese and international patents on PD-1/PD-L1 antibodies, focusing on sequence variants and manufacturing methods.
Patentability Consideration
- Claims focus on novel amino acid sequences with demonstrated improved clinical performance in preclinical or early-phase trials.
- The uniqueness lies in sequence modifications designed to optimize binding affinity and stability.
Competitor Landscape
Major competitors include:
- Merck & Co: Keytruda patents.
- Bristol-Myers Squibb: Opdivo patents.
- Incyte: Focused on PD-1/PD-L1 pathways.
- Innovator patent families: Covering antibody sequences and manufacturing methods.
Junshi's patent may complement or challenge existing patents, especially if sequence modifications are sufficiently distinct to avoid infringement.
Legal status and potential challenges
- Issued: Patent CN112888431 is active as of current.
- Potential Infringement Risks: Given claims on antibody sequences, market entry may require licensing or opposition strategies.
- Opposition grounds: Could include prior art referencing similar sequences or manufacturing methods.
Market implications
- The patent secures exclusive rights in China until at least 2042, provided maintenance fees are paid.
- The broad claims enhance Junshi Biosciences' competitive position, especially if these antibodies demonstrate therapeutic advantages.
- Parallel filings in other jurisdictions amplify the patent's global enforcement prospects.
Summary Evaluation
| Aspect |
Assessment |
| Patent strength |
Strong, due to focused claims on specific antibody sequences and manufacturing methods. |
| Innovation level |
Claims involve novel sequence modifications targeting improved efficacy. |
| Competitiveness |
Significant, considering China's growing biotech infrastructure and market expansion. |
| Risks |
Potential patent overlaps with existing antibody patents, requiring strategic analysis. |
Key Takeaways
- CN112888431 covers specific monoclonal antibody sequences targeting PD-1/PD-L1 pathways, with claims extending to manufacturing and therapeutic uses.
- The patent's broad scope includes sequence modifications that differentiate it from prior art, primarily for improved clinical performance.
- It aligns with a strategic international patent portfolio, with filings across key jurisdictions.
- The patent landscape around PD-1/PD-L1 antibodies remains crowded, but specific sequence variants may offer competitive differentiation.
- Enforcement and licensing negotiations will depend on detailed patent claim analysis and patent law developments in China.
FAQs
- Does CN112888431 cover all PD-1 antibodies? No, it claims specific antibody sequences and their modifications, not all PD-1 antibodies.
- Are the claims limited to China? The patent is enforceable in China only; international counterparts have been filed through PCT.
- Can existing PD-1 antibodies infringe on this patent? If they do not include the claimed sequences or modifications, they are less likely to infringe.
- What is the potential expiry date? Assuming maintenance fees are paid, expiry could be around 2042, 20 years from filing.
- Could this patent be challenged? Yes, on grounds of novelty or inventive step, especially regarding antibody sequence prior art.
References
[1] Junshi Biosciences. (2022). Patent CN112888431. State Intellectual Property Office of China.
[2] World Intellectual Property Organization. (2022). International Patent Applications.
[3] United States Patent and Trademark Office. (2023). Patent Application Data.
[4] European Patent Office. (2023). Patent Search Reports.
